TRIL

Trillium Therapeutics (TRIL)

Trillium Therapeutics Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:TRIL

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2021/11/22	20 : 05	Edgar (US Regulatory)	Notice of Effectiveness (effect)	NASDAQ:TRIL	Trillium Therapeutics Inc
2021/11/20	05 : 34	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:TRIL	Trillium Therapeutics Inc
2021/11/20	03 : 34	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:TRIL	Trillium Therapeutics Inc
2021/11/20	03 : 33	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:TRIL	Trillium Therapeutics Inc
2021/11/20	03 : 31	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:TRIL	Trillium Therapeutics Inc
2021/11/20	03 : 30	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:TRIL	Trillium Therapeutics Inc
2021/11/20	03 : 28	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:TRIL	Trillium Therapeutics Inc
2021/11/20	03 : 28	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:TRIL	Trillium Therapeutics Inc
2021/11/20	03 : 27	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:TRIL	Trillium Therapeutics Inc
2021/11/20	03 : 25	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:TRIL	Trillium Therapeutics Inc
2021/11/20	03 : 22	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:TRIL	Trillium Therapeutics Inc
2021/11/20	03 : 21	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:TRIL	Trillium Therapeutics Inc
2021/11/19	20 : 44	Edgar (US Regulatory)	Amended Statement of Beneficial Ownership (sc 13d/a)	NASDAQ:TRIL	Trillium Therapeutics Inc
2021/11/18	06 : 02	Edgar (US Regulatory)	Post-effective Amendment to an S-8 Filing (s-8 Pos)	NASDAQ:TRIL	Trillium Therapeutics Inc
2021/11/18	06 : 02	Edgar (US Regulatory)	Post-effective Amendment to an Automatic Shelf Registration of Form S-3asr or Form F-3asr (posasr)	NASDAQ:TRIL	Trillium Therapeutics Inc
2021/11/18	06 : 02	Edgar (US Regulatory)	Post-effective Amendment to an S-8 Filing (s-8 Pos)	NASDAQ:TRIL	Trillium Therapeutics Inc
2021/11/18	06 : 01	Edgar (US Regulatory)	Post-effective Amendment to Registration Statement (pos Am)	NASDAQ:TRIL	Trillium Therapeutics Inc
2021/11/18	06 : 01	Edgar (US Regulatory)	Post-effective Amendment to Registration Statement (pos Am)	NASDAQ:TRIL	Trillium Therapeutics Inc
2021/11/17	23 : 28	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:TRIL	Trillium Therapeutics Inc
2021/11/17	23 : 24	Edgar (US Regulatory)	Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)	NASDAQ:TRIL	Trillium Therapeutics Inc
2021/11/17	07 : 08	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:TRIL	Trillium Therapeutics Inc
2021/11/16	07 : 07	Edgar (US Regulatory)	Amended Statement of Ownership (sc 13g/a)	NASDAQ:TRIL	Trillium Therapeutics Inc
2021/11/12	21 : 01	Edgar (US Regulatory)	Quarterly Report (10-q)	NASDAQ:TRIL	Trillium Therapeutics Inc
2021/10/29	19 : 08	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:TRIL	Trillium Therapeutics Inc
2021/10/29	06 : 00	GlobeNewswire Inc.	Trillium Therapeutics Receives Final Court Order Approving Arrangement	NASDAQ:TRIL	Trillium Therapeutics Inc
2021/10/27	19 : 07	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:TRIL	Trillium Therapeutics Inc
2021/10/27	06 : 15	GlobeNewswire Inc.	Trillium Securityholders Approve Acquisition by Pfizer	NASDAQ:TRIL	Trillium Therapeutics Inc
2021/10/20	19 : 05	Edgar (US Regulatory)	Additional Proxy Soliciting Materials (definitive) (defa14a)	NASDAQ:TRIL	Trillium Therapeutics Inc
2021/10/20	19 : 04	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:TRIL	Trillium Therapeutics Inc
2021/10/15	19 : 34	Edgar (US Regulatory)	Additional Proxy Soliciting Materials (definitive) (defa14a)	NASDAQ:TRIL	Trillium Therapeutics Inc